Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
APL-4098 Alone and in Combination With Azacitidine and Venetoclax in AML, MDS/AML or MDS-EB
NCT06372717Phase 1Recruiting
- Sponsor
- Apollo Therapeutics
- Start
- Jun 2024
- Primary completion
- Jul 2027
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 1, open-label trial of APL-4098 in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) (3 arms), sponsored by Apollo Therapeutics. Primary endpoints: Incidence of Treatment Emergent Adverse Events at 1 year, Incidence of Dose Limiting Toxicities at 4 weeks and 2 more. Started Jun 2024; status: recruiting.
02
Drugs
APL-4098
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT06372717.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06372717.